JP Morgan Chase’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-113,485
| Closed | -$19.5M | – | 7260 |
|
|
2021
Q3 | $19.5M | Buy |
113,485
+61,329
| +118% | +$8.02M | ﹤0.01% | 1785 |
|
|
2021
Q2 | $6.54M | Sell |
52,156
-6,546
| -11% | -$826K | ﹤0.01% | 2811 |
|
|
2021
Q1 | $7.96M | Buy |
58,702
+11,719
| +25% | +$1.51M | ﹤0.01% | 2572 |
|
|
2020
Q4 | $6.01M | Sell |
46,983
-128,160
| -73% | -$15M | ﹤0.01% | 2641 |
|
|
2020
Q3 | $19.8M | Buy |
175,143
+88,055
| +101% | +$8.77M | ﹤0.01% | 1498 |
|
|
2020
Q2 | $8.3M | Buy |
87,088
+1,944
| +2% | +$187K | ﹤0.01% | 2052 |
|
|
2020
Q1 | $7.65M | Sell |
85,144
-702
| -0.8% | -$54.6K | ﹤0.01% | 1936 |
|
|
2019
Q4 | $4.55M | Buy |
85,846
+14,855
| +21% | +$677K | ﹤0.01% | 2759 |
|
|
2019
Q3 | $2.81M | Buy |
70,991
+3,353
| +5% | +$145K | ﹤0.01% | 3182 |
|
|
2019
Q2 | $2.77M | Sell |
67,638
-6,649
| -9% | -$275K | ﹤0.01% | 3154 |
|
|
2019
Q1 | $3.46M | Buy |
74,287
+34,195
| +85% | +$1.5M | ﹤0.01% | 2898 |
|
|
2018
Q4 | $1.75M | Buy |
40,092
+36
| +0.1% | +$1.8K | ﹤0.01% | 3378 |
|
|
2018
Q3 | $2.29M | Sell |
40,056
-11,069
| -22% | -$544K | ﹤0.01% | 3365 |
|
|
2018
Q2 | $2.48M | Sell |
51,125
-39,517
| -44% | -$1.44M | ﹤0.01% | 3252 |
|
|
2018
Q1 | $3.54M | Sell |
90,642
-4,657
| -5% | -$198K | ﹤0.01% | 2857 |
|
|
2017
Q4 | $4.04M | Buy |
95,299
+3,399
| +4% | +$127K | ﹤0.01% | 2852 |
|
|
2017
Q3 | $3.29M | Buy |
+91,900
| New | +$3.19M | ﹤0.01% | 2865 |
|
|
2017
Q2 | – | Sell |
-124,975
| Closed | -$3.31M | – | 5333 |
|
|
2017
Q1 | $3.31M | Sell |
124,975
-703,836
| -85% | -$18.5M | ﹤0.01% | 2710 |
|
|
2016
Q4 | $21.1M | Buy |
828,811
+27,066
| +3% | +$858K | 0.01% | 1430 |
|
|
2016
Q3 | $29M | Buy |
801,745
+2,046
| +0.3% | +$67.8K | 0.01% | 1130 |
|
|
2016
Q2 | $27.2M | Buy |
799,699
+5,865
| +0.7% | +$191K | 0.01% | 1180 |
|
|
2016
Q1 | $20.9M | Sell |
793,834
-44,926
| -5% | -$1.31M | 0.01% | 1304 |
|
|
2015
Q4 | $40.9M | Buy |
838,760
+158,023
| +23% | +$5.69M | 0.01% | 907 |
|
|
2015
Q3 | $17M | Sell |
680,737
-6,334
| -0.9% | -$190K | ﹤0.01% | 1384 |
|
|
2015
Q2 | $21.7M | Sell |
687,071
-21,169
| -3% | -$683K | 0.01% | 1348 |
|
|
2015
Q1 | $27M | Buy |
708,240
+42,693
| +6% | +$1.7M | 0.01% | 1238 |
|
|
2014
Q4 | $25.9M | Buy |
665,547
+130,663
| +24% | +$4.55M | 0.01% | 1306 |
|
|
2014
Q3 | $16.2M | Buy |
534,884
+56,578
| +12% | +$1.59M | ﹤0.01% | 1585 |
|
|
2014
Q2 | $16.2M | Sell |
478,306
-27,648
| -5% | -$925K | ﹤0.01% | 1458 |
|
|
2014
Q1 | $17.5M | Sell |
505,954
-260,126
| -34% | -$11.7M | ﹤0.01% | 1401 |
|
|
2013
Q4 | $30.3M | Buy |
+766,080
| New | +$18.5M | 0.01% | 1067 |
|
JP Morgan Chase's XLRN Position: Q4 2021 in Review
JP Morgan Chase sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 113,485 shares — an estimated $19.5M sold.
JP Morgan Chase first reported a position in XLRN in Q4 2013 and held it in 31 quarters. The position peaked at $40.9M in Q4 2015. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- JP Morgan Chase reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- JP Morgan Chase sold 113,485 Acceleron Pharma shares in Q4 2021, an estimated $19.5M.
- JP Morgan Chase first reported a position in Acceleron Pharma in Q4 2013 and held it in 31 quarters.
- JP Morgan Chase's Acceleron Pharma position peaked at $40.9M in Q4 2015.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.